Search results
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 6 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the ...
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena via Yahoo Finance· 2 days agoFrom the dose level 1 cohort, there was one case of dose-limiting toxicity of febrile neutropenia....
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 4 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S....
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 3 days agoData from the same showed that treatment with Descartes-08 was generally well-tolerated, with no...
Biogen to acquire HI-Bio for up to $1.8 billion By Investing.com
Investing.com· 4 days agos portfolio in immunology and rare diseases. HI-Bio's lead asset, felzartamab, is an anti-CD38...
Octapharma USA Appoints New VP of Commercial Marketing & Development
New Jersey Business Magazine· 6 days agoOctapharma USA, Inc. has appointed pharmaceutical industry veteran Kelly Hearn as vice president of...
Zydus Lifesciences concludes subject enrolment in Phase II ALS trial
Clinical Trials Arena via Yahoo Finance· 2 days agoThe company has already established Phase II proof-of-concept in cryopyrin-associated periodic...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks via Yahoo Finance· 4 days agoNomlabofusp has received Rare Pediatric Disease designation, Fast Track designation and Orphan Drug ...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 3 days agoHI-Bio has plans to advance felzartamab into phase III for all indications. HI-Bio has received...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 5 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...